A high tumour burden has long been associated with inferior outcomes on traditional cancer therapies and emerging evidence suggests that tumour burden is particularly relevant for patients receiving immune-checkpoint inhibitors. Here, the authors summarize the available clinical and preclinical evidence for the role of tumour burden in determining the outcomes of patients receiving immune-checkpoint inhibitors and highlight areas that are likely to be of future research interest in this emerging area.
- Filippo G. Dall’Olio
- Aurélien Marabelle
- Benjamin Besse
